Travere Therapeutics (TVTX) Skyrockets to Fresh High as FDA Concerns on Drug Candidate Subside

We recently published AI Frenzy: 10 Stocks Crushing the Market, 6 Climb to Fresh Highs. Travere Therapeutics, Inc. (NASDAQ:TVTX) is one of the top performers on Wednesday.

Travere Therapeutics, Inc. (NASDAQ:TVTX) soared to a new all-time high on Wednesday, as investors cheered the Food and Drug Administration’s (FDA) decision to cancel the creation of an advisory committee that would support the review of its drug application to treat focal segmental glomerulosclerosis (FSGS).

During the session, Travere Therapeutics, Inc. (NASDAQ:TVTX) touched its highest price of $28.69 before trimming gains to end the day just up by 26.2 percent at $27.31 apiece.

Investors took the decision positively as dropping the supposed advisory committee suggested that the FDA now has fewer concerns about the drug candidate.

Called Filspari, it would be the first ever treatment for FSGS, a leading cause of kidney failures.

“We are pleased with the progress of the sNDA to date and look forward to further supporting the FDA’s review of our application for Filspari in FSGS,” said Travere Therapeutics, Inc. (NASDAQ:TVTX) President and CEO Eric Dube.

Expected to be approved by January 2026, Travere Therapeutics, Inc. (NASDAQ:TVTX) said it is now in preparations for the commercial launch.

Filspari is an oral, non-immunosuppressive potential therapy that targets podocyte injury, a key driver of FSGS progression.

“FSGS is a leading cause of kidney failure, and for too long, patients have been waiting for approved therapies for this rare and devastating disease,” Dube said.

While we acknowledge the potential of TVTX as an investment, our conviction lies in the belief that some AI stocks hold greater promise for delivering higher returns and have limited downside risk. If you are looking for an extremely cheap AI stock that is also a major beneficiary of Trump tariffs and onshoring, see our free report on the best short-term AI stock.

READ NEXT: 30 Stocks That Should Double in 3 Years and 11 Hidden AI Stocks to Buy Right Now.

Disclosure: None. This article is originally published at Insider Monkey.